The clinical failure is contained by the protective deal structure, but it removes a potential upside catalyst from the portfolio. Traders should watch for any further pipeline updates or changes to the 2030 receipts target, though the reiteration of the $4.7B+ target provides near-term support.
Price Chart
Executive Summary
Royalty Pharma announced that Novartis' Phase 3 HORIZON trial for pelacarsen failed to meet its primary endpoint in atherosclerotic cardiovascular disease. The company's $500 million Ionis funding agreement was structured with $350 million allocated to Spinraza royalties and only $150 million to pelacarsen, and Royalty Pharma expects to recoup its total investment and earn a modest positive return. The company reiterated its 2030 Portfolio Receipts target of $4.7 billion or more, limiting the financial damage from this clinical failure.
Key Financial Metrics
Key Facts
- Novartis' Phase 3 HORIZON trial for pelacarsen did not meet its primary endpoint in atherosclerotic cardiovascular disease.
- Royalty Pharma's $500 million Ionis funding agreement allocated $350 million to Spinraza royalties and $150 million to pelacarsen royalties.
- Royalty Pharma expects to recoup its total investment and earn a modest positive return despite the pelacarsen failure.
- Royalty Pharma reiterates its 2030 Portfolio Receipts target of $4.7 billion or more.
- No milestone payments will be made to Ionis following the HORIZON results.
Financial Impact
$150 million of the $500 million Ionis funding was allocated to pelacarsen royalties; the company expects to recoup total investment and earn a modest positive return, with no milestone payments due.
Risk Factors
- Further clinical setbacks in Royalty Pharma's development-stage portfolio could pressure the stock.
- The pelacarsen failure removes a potential growth driver, limiting upside optionality.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3356846 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | Press Release | $60.59 $58.47 | ▲ +3.50% | ▲ +2.38% | $57.16 (+5.66%) |
Aug 19, 2026 6w ago | Insider Cluster | $61.73 $61.80 | ▲ +0.11% | ▲ +0.50% | $57.16 (−7.40%) |
Aug 12, 2026 7w ago | 144 | $58.56 $60.58 | ▲ +3.45% | ▲ +5.41% | $57.16 (−2.39%) |
Aug 5, 2026 8w ago | 8-K | $57.75 $59.22 | ▲ +2.55% | ▲ +2.19% | $57.16 (−1.02%) |
Jul 2, 2026 13w ago | Insider Cluster | $57.77 $57.96 | ▲ +0.33% | ▼ −0.60% | $57.16 (−1.06%) |
Jul 2, 2026 13w ago | Insider Cluster | $57.77 $57.96 | ▲ +0.33% | ▼ −0.60% | $57.16 (−1.06%) |
May 28, 2026 18w ago | Insider Cluster | $55.76 $55.87 | ▲ +0.20% | ▲ +2.72% | $57.16 (+2.51%) |
May 28, 2026 18w ago | 8-K | $55.76 $54.97 | ▼ −1.42% | ▼ −1.12% | $57.16 (+2.51%) |
May 22, 2026 19w ago | Insider Cluster | $54.50 $55.18 | ▲ +1.25% | ▼ −0.41% | $57.16 (+4.88%) |
May 15, 2026 19w ago | Insider Cluster | $52.07 $53.86 | ▲ +3.44% | ▲ +1.82% | $57.16 (+9.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access